terbutaline has been researched along with Myasthenia Gravis in 4 studies
Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.
terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.
Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to assess the short-term efficacy and safety of terbutaline, a beta2-adrenergic agonist, in patients with myasthenia gravis (MG) in a randomized, double-blind, placebo-controlled, crossover study." | 9.14 | Terbutaline in myasthenia gravis: a pilot study. ( Arnason, BG; Gundogdu, B; Harding-Clay, B; Oger, J; Rezania, K; Soliven, B, 2009) |
| "The objective of this study was to assess the short-term efficacy and safety of terbutaline, a beta2-adrenergic agonist, in patients with myasthenia gravis (MG) in a randomized, double-blind, placebo-controlled, crossover study." | 5.14 | Terbutaline in myasthenia gravis: a pilot study. ( Arnason, BG; Gundogdu, B; Harding-Clay, B; Oger, J; Rezania, K; Soliven, B, 2009) |
| "The effect of intravenous injection of propranolol, verapamil, terbutaline, calcium, and edrophonium on neuromuscular transmission has been studied with repetitive nerve stimulation and clinical tests in 10 patients with myasthenia gravis (MG)." | 3.69 | Acute effects of intravenous injection of beta-adrenoreceptor- and calcium channel at antagonists and agonists in myasthenia gravis. ( Bjelak, S; Jonkers, I; Matell, G; Pirskanen, R; Swerup, C, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Soliven, B | 1 |
| Rezania, K | 1 |
| Gundogdu, B | 1 |
| Harding-Clay, B | 1 |
| Oger, J | 1 |
| Arnason, BG | 1 |
| Chelmicka-Schorr, E | 1 |
| Wollmann, RL | 1 |
| Kwasniewski, MN | 1 |
| Kim, DH | 1 |
| Dupont, BL | 1 |
| Jonkers, I | 2 |
| Swerup, C | 2 |
| Pirskanen, R | 2 |
| Bjelak, S | 2 |
| Matell, G | 2 |
| Van Vliet, J | 1 |
1 trial available for terbutaline and Myasthenia Gravis
| Article | Year |
|---|---|
Terbutaline in myasthenia gravis: a pilot study.
Topics: Adrenergic beta-Agonists; Adult; Aged; Cholinesterase Inhibitors; Cross-Over Studies; Double-Blind M | 2009 |
3 other studies available for terbutaline and Myasthenia Gravis
| Article | Year |
|---|---|
The beta 2-adrenergic agonist terbutaline suppresses acute passive transfer experimental autoimmune myasthenia gravis (EAMG).
Topics: Acute Disease; Animals; Antibodies, Monoclonal; Electromyography; Female; Immunization, Passive; Imm | 1993 |
Acute effects of intravenous injection of beta-adrenoreceptor- and calcium channel at antagonists and agonists in myasthenia gravis.
Topics: Adult; Aged; Edrophonium; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Organometallic Compo | 1996 |
Calcium channel and beta-receptor antagonists and agonists in MG.
Topics: Administration, Oral; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Calcium Channel Blocker | 1998 |